55KRC: UP-NEXT study tests ovarian cancer treatment
The University of Cincinnati's Amanda Jackson, MD, recently joined 55KRC's Simply Medicine program to discuss the UP-NEXT ovarian cancer clinical trial. Jackson is the site principal investigator at UC for the UP-NEXT trial that is testing a new treatment for a subset of ovarian cancer patients.
"Patients with ovarian cancer, when they initially get chemotherapy, a good percentage of them will go into remission or not have active cancer," said Jackson, University of Cincinnati Cancer Center physician-researcher and associate professor, division chief and vice chair in the UC College of Medicine’s Department of Obstetrics & Gynecology. "But unfortunately a good percentage of those patients’ cancer will come back and be recurrent cancer."
The trial is testing the effectiveness of an antibody-drug conjugate (upifitamab rilsodotin) that is part of a class of therapeutics that have proven to be successful treatments for other types of cancer. The drug works as a kind of Trojan horse, binding to a specific antigen often found on the surface of ovarian cancer cells.
"This study is looking specifically at figuring out medications that we can give to that group of patients after they finish chemo, after we get their cancer to decrease in size, to keep their cancer at bay, to give them a longer period of time before their cancer would come back," she said.
Learn more about the research.
Listen to the Simply Medicine segment. (Note: Segment begins around 3:00 mark of episode.)
Featured photo at top: ovarian cancer tumor in animal model. Photo/National Cancer Institute.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.